Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$64.10
-1.01-1.55%
al cierre: -
$63.76
-0.34-0.53%
After hour: Oct 10, 4:04 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Halozyme Therapeutics Inc ha un obiettivo di prezzo di consenso pari a $67.2, stabilito in base alle ultime valutazioni degli analisti di 15. Le ultime 3 valutazioni degli analisti sono state rilasciate da HC Wainwright & Co., Benchmark y HC Wainwright & Co. il octubre 2, 2025, septiembre 24, 2025 y septiembre 22, 2025. Con un obiettivo di prezzo medio di $88.33 tra le HC Wainwright & Co., Benchmark y HC Wainwright & Co., c'è un implicito 38.54% upside per Halozyme Therapeutics Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
HC Wainwright & Co.
Benchmark
Morgan Stanley
JP Morgan
JMP Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Halozyme Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/02/2025 | 41.15% | HC Wainwright & Co. | $85 → $90 | Maintains | Buy | |||
09/24/2025 | 41.15% | Benchmark | $75 → $90 | Maintains | Buy | |||
09/22/2025 | 33.31% | HC Wainwright & Co. | $75 → $85 | Maintains | Buy | |||
08/18/2025 | 25.47% | Morgan Stanley | $75 → $80 | Maintains | Overweight | |||
08/07/2025 | -1.19% | JP Morgan | $60 → $63 | Maintains | Neutral | |||
08/06/2025 | 42.72% | JMP Securities | $78 → $91 | Maintains | Market Outperform | |||
08/06/2025 | 17.63% | HC Wainwright & Co. | $72 → $75 | Maintains | Buy | |||
08/06/2025 | 17.63% | Morgan Stanley | $62 → $75 | Upgrade | Equal-Weight → Overweight | |||
07/16/2025 | -5.9% | JP Morgan | $58 → $60 | Maintains | Neutral | |||
05/29/2025 | 12.92% | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
05/14/2025 | -2.76% | Morgan Stanley | $73 → $62 | Downgrade | Overweight → Equal-Weight | |||
05/13/2025 | -26.29% | Leerink Partners | — | → $47 | Downgrade | Market Perform → Underperform | ||
05/07/2025 | 14.49% | Morgan Stanley | $67 → $73 | Maintains | Overweight | |||
05/07/2025 | 1.94% | Wells Fargo | $60 → $65 | Maintains | Equal-Weight | |||
04/25/2025 | 12.92% | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
04/21/2025 | -9.03% | JP Morgan | $55 → $58 | Maintains | Neutral | |||
03/06/2025 | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | |||
02/20/2025 | 17.63% | Benchmark | $75 → $75 | Reiterates | Buy → Buy | |||
02/19/2025 | 12.92% | HC Wainwright & Co. | $70 → $72 | Maintains | Buy | |||
02/14/2025 | 5.08% | Morgan Stanley | → $67 | Assumes | → Overweight | |||
02/04/2025 | 9.79% | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
01/13/2025 | -10.6% | Wells Fargo | $62 → $57 | Maintains | Equal-Weight | |||
01/10/2025 | -16.88% | Piper Sandler | $52 → $53 | Maintains | Neutral | |||
01/10/2025 | 9.79% | HC Wainwright & Co. | $68 → $70 | Maintains | Buy | |||
12/30/2024 | 6.65% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
12/18/2024 | 6.65% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
11/25/2024 | 6.65% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
11/20/2024 | 6.65% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
11/04/2024 | -18.44% | Piper Sandler | $51 → $52 | Maintains | Neutral | |||
11/01/2024 | 14.49% | JMP Securities | $72 → $73 | Maintains | Market Outperform | |||
11/01/2024 | 6.65% | HC Wainwright & Co. | $65 → $68 | Maintains | Buy | |||
10/25/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
10/07/2024 | -2.76% | Wells Fargo | $58 → $62 | Downgrade | Overweight → Equal-Weight | |||
10/04/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
09/19/2024 | -10.6% | JP Morgan | $52 → $57 | Downgrade | Overweight → Neutral | |||
09/16/2024 | 17.63% | Benchmark | $60 → $75 | Maintains | Buy | |||
09/16/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
09/13/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
08/08/2024 | -5.9% | Benchmark | $60 → $60 | Reiterates | Buy → Buy | |||
08/08/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
08/07/2024 | 1.94% | TD Cowen | $59 → $65 | Maintains | Buy | |||
08/07/2024 | 0.38% | Morgan Stanley | $59 → $64 | Maintains | Overweight | |||
08/06/2024 | -18.44% | JP Morgan | $53 → $52 | Maintains | Overweight | |||
08/01/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
07/22/2024 | -23.15% | Goldman Sachs | $44 → $49 | Maintains | Neutral | |||
07/16/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/26/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/25/2024 | -5.9% | Benchmark | $50 → $60 | Maintains | Buy | |||
06/24/2024 | 1.94% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/07/2024 | -20.01% | Piper Sandler | $48 → $51 | Downgrade | Overweight → Neutral | |||
06/07/2024 | -9.03% | Wells Fargo | $48 → $58 | Maintains | Overweight | |||
06/07/2024 | 1.94% | HC Wainwright & Co. | $50 → $65 | Maintains | Buy | |||
06/04/2024 | -21.58% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/22/2024 | -21.58% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/08/2024 | 11.36% | JMP Securities | $72 → $71 | Maintains | Market Outperform | |||
05/08/2024 | -21.58% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy | |||
05/07/2024 | -21.58% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy | |||
04/30/2024 | -21.58% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/17/2024 | -21.58% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/16/2024 | -21.58% | Benchmark | $50 → $50 | Reiterates | Buy → Buy | |||
02/29/2024 | -15.31% | TD Cowen | → $54 | Initiates | → Outperform | |||
02/21/2024 | 12.92% | JMP Securities | $72 → $72 | Reiterates | Market Outperform → Market Outperform | |||
02/21/2024 | -21.58% | HC Wainwright & Co. | $48 → $50 | Maintains | Buy | |||
01/19/2024 | -24.72% | HC Wainwright & Co. | $48 → $48 | Reiterates | Buy → Buy | |||
01/19/2024 | -21.58% | Benchmark | $50 → $50 | Reiterates | Buy → Buy | |||
01/18/2024 | 12.92% | JMP Securities | $72 → $72 | Reiterates | Market Outperform → Market Outperform | |||
01/18/2024 | -37.26% | Goldman Sachs | $45 → $40 | Maintains | Neutral | |||
01/18/2024 | -24.72% | HC Wainwright & Co. | $61 → $48 | Maintains | Buy | |||
12/26/2023 | -7.47% | Morgan Stanley | $61 → $59 | Maintains | Overweight | |||
10/20/2023 | -21.58% | Benchmark | → $50 | Reiterates | Buy → Buy | |||
10/19/2023 | -4.33% | HC Wainwright & Co. | $60 → $61 | Maintains | Buy | |||
10/09/2023 | -5.9% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy | |||
09/08/2023 | -5.9% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy | |||
08/30/2023 | -5.9% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy | |||
08/15/2023 | -5.9% | HC Wainwright & Co. | $61 → $60 | Maintains | Buy | |||
08/10/2023 | -4.33% | Morgan Stanley | $60 → $61 | Maintains | Overweight | |||
07/24/2023 | -4.33% | HC Wainwright & Co. | → $61 | Initiates | → Buy | |||
07/24/2023 | -29.42% | Goldman Sachs | $43 → $45 | Downgrade | Buy → Neutral | |||
05/10/2023 | 3.51% | JMP Securities | → $66 | Reiterates | → Market Outperform | |||
05/10/2023 | -5.9% | Morgan Stanley | $64 → $60 | Maintains | Overweight | |||
05/10/2023 | -27.85% | Piper Sandler | → $46 | Upgrade | Neutral → Overweight | |||
03/27/2023 | -9.03% | Berenberg | → $58 | Reinstates | → Buy | |||
03/17/2023 | -24.72% | Wells Fargo | $55 → $48 | Maintains | Overweight | |||
03/16/2023 | -34.13% | SVB Leerink | → $42 | Downgrade | Outperform → Market Perform | |||
03/16/2023 | -13.74% | Wells Fargo | $65 → $55 | Maintains | Overweight | |||
03/06/2023 | 0.38% | Morgan Stanley | $65 → $64 | Maintains | Overweight | |||
02/23/2023 | -18.44% | JP Morgan | $54 → $52 | Maintains | Overweight | |||
02/22/2023 | 3.51% | JMP Securities | $62 → $66 | Reiterates | → Market Outperform | |||
01/11/2023 | -4.33% | SVB Leerink | $62 → $61 | Maintains | Outperform | |||
12/21/2022 | 1.94% | Morgan Stanley | $53 → $65 | Maintains | Overweight | |||
12/08/2022 | 6.65% | Benchmark | $55 → $68 | Maintains | Buy | |||
11/28/2022 | 1.94% | Wells Fargo | → $65 | Initiates | → Overweight | |||
11/22/2022 | -15.31% | JP Morgan | $53 → $54 | Maintains | Overweight | |||
11/14/2022 | -2.76% | SVB Leerink | $52 → $62 | Maintains | Outperform | |||
11/09/2022 | -2.76% | JMP Securities | $60 → $62 | Maintains | Market Outperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Halozyme Therapeutics (HALO)?
El último precio objetivo de Halozyme Therapeutics (NASDAQ:HALO) fue comunicado por HC Wainwright & Co. el octubre 2, 2025. La firma de analistas fijó un precio objetivo para $90.00 que espera HALO a rise dentro de 12 meses (un posible 41.15% upside). 32 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Halozyme Therapeutics (HALO)?
La última calificación de analistas para Halozyme Therapeutics (NASDAQ:HALO) fue proporcionada por HC Wainwright & Co., y Halozyme Therapeutics mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de Halozyme Therapeutics (HALO)?
La última revisión al alza de Halozyme Therapeutics Inc se produjo en agosto 6, 2025, cuando Morgan Stanley elevó su precio objetivo a $75. Morgan Stanley anteriormente tenía an equal-weight para Halozyme Therapeutics Inc.
¿Cuándo fue la última revisión a la baja de Halozyme Therapeutics (HALO)?
La última revisión a la baja de Halozyme Therapeutics Inc se produjo en mayo 14, 2025, cuando Morgan Stanley cambió su precio objetivo de $73 a $62 para Halozyme Therapeutics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Halozyme Therapeutics (HALO)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Halozyme Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Halozyme Therapeutics se registró el octubre 2, 2025, por lo que la próxima calificación estará disponible en torno al octubre 2, 2026.
¿Es correcta la calificación de los analistas sobre Halozyme Therapeutics (HALO)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Halozyme Therapeutics (HALO) fue un mantuvo con un precio objetivo de $85.00 a $90.00. El precio actual al que cotiza Halozyme Therapeutics (HALO) es de $63.76, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.